Marketing is the weakness for Aussie bio stocks which want to have market share in US, my other holding TD1 has the same problem as ANP, great product, equal or greater compared to their US counterpart(s), but does not have the fund and resources to open market in US, have to team up with US company and sell themselves short…… but even so is great, the first step of a long journey years to come
